These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 30285924

  • 1. Epidemiological dynamic modeling of human papillomavirus-related diseases to assess vaccination strategies in Argentina.
    Borracci RA, Segal SV, Méndez JH.
    Medicina (B Aires); 2018; 78(5):315-328. PubMed ID: 30285924
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T, Lutsar K, Uusküla A, Padrik L, Raud T, Reile R, Nahkur O, Kiivet RA.
    Vaccine; 2017 Nov 01; 35(46):6329-6335. PubMed ID: 28899625
    [Abstract] [Full Text] [Related]

  • 3. Cancers attributable to human papillomavirus infection.
    Grulich AE, Jin F, Conway EL, Stein AN, Hocking J.
    Sex Health; 2010 Sep 01; 7(3):244-52. PubMed ID: 20719211
    [Abstract] [Full Text] [Related]

  • 4. Comprehensive control of human papillomavirus infections and related diseases.
    Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S, authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012.
    Vaccine; 2013 Dec 29; 31 Suppl 5():F1-31. PubMed ID: 24331745
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels.
    Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, Cronin KA, Watson M, Schiffman M, Henley SJ, Schymura MJ, Anderson RN, Yankey D, Edwards BK.
    J Natl Cancer Inst; 2013 Feb 06; 105(3):175-201. PubMed ID: 23297039
    [Abstract] [Full Text] [Related]

  • 7. Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis.
    Bogaards JA, Wallinga J, Brakenhoff RH, Meijer CJ, Berkhof J.
    BMJ; 2015 May 12; 350():h2016. PubMed ID: 25985328
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
    Wolff E, Elfström KM, Haugen Cange H, Larsson S, Englund H, Sparén P, Roth A.
    Vaccine; 2018 Aug 16; 36(34):5160-5165. PubMed ID: 30017146
    [Abstract] [Full Text] [Related]

  • 12. Human Papillomavirus-Attributable Cancers - United States, 2012-2016.
    Senkomago V, Henley SJ, Thomas CC, Mix JM, Markowitz LE, Saraiya M.
    MMWR Morb Mortal Wkly Rep; 2019 Aug 23; 68(33):724-728. PubMed ID: 31437140
    [Abstract] [Full Text] [Related]

  • 13. Beyond cervical cancer: burden of other HPV-related cancers among men and women.
    Chaturvedi AK.
    J Adolesc Health; 2010 Apr 23; 46(4 Suppl):S20-6. PubMed ID: 20307840
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.
    Luttjeboer J, Westra TA, Wilschut JC, Nijman HW, Daemen T, Postma MJ.
    Vaccine; 2013 Aug 20; 31(37):3922-7. PubMed ID: 23806241
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France.
    Riethmuller D, Jacquard AC, Lacau St Guily J, Aubin F, Carcopino X, Pradat P, Dahlab A, Prétet JL.
    BMC Public Health; 2015 May 02; 15():453. PubMed ID: 25934423
    [Abstract] [Full Text] [Related]

  • 17. The HPV infection in males: an update.
    Giraldi G, De Luca d'Alessandro E.
    Ann Ig; 2012 May 02; 24(6):497-506. PubMed ID: 23234187
    [Abstract] [Full Text] [Related]

  • 18. [Anticipated efficacy of HPV vaccination in prophylaxis against nongenital cancers].
    Sehnal B, Vojáčková N, Driák D, Kmoníčková E, Vaňousová D, Maxová K, Neumannová H, Sláma J.
    Klin Onkol; 2014 May 02; 27(4):239-46. PubMed ID: 25115712
    [Abstract] [Full Text] [Related]

  • 19. Ten Years of Human Papillomavirus Vaccination in the United States.
    Markowitz LE, Gee J, Chesson H, Stokley S.
    Acad Pediatr; 2018 Mar 02; 18(2S):S3-S10. PubMed ID: 29502635
    [Abstract] [Full Text] [Related]

  • 20. [The disease burden of human papillomavirus in men is substantial and can potentially be prevented].
    Kiellberg Larsen H, Kofoed K, Sand C.
    Ugeskr Laeger; 2013 Feb 04; 175(6):349-53. PubMed ID: 23402241
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.